Maryland Momentum Fund and VTC Innovation Fund have both contributed to a series A round for Veralox Therapeutics, which is focusing on diseases with unmet needs.

Veralox Therapeutics, a US-based biotechnology developer advancing research from the US National Institutes of Health (NIH) and multiple universities, has completed a $16.6m series A round featuring Maryland Momentum Fund and VTC Innovation Fund. The two funds, affiliated with University System of Maryland and Virginia Tech respectively, were joined by Hatteras Venture Partners, which led…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.